Mumbai: Drugmaker, Lupin, has recently announced that the US Food and Drug Administration (USFDA) has concluded an inspection with four observations at the company's Tarapur manufacturing facility.

The inspection was carried out between March 22, 2022 and April 4, 2022.

"We are confident of addressing the observations to the U.S. FDA's satisfaction. We are committed to adherence and full compliance with CGMP regulations and uphold the highest quality standards across our manufacturing sites," the company said in a BSE filing.

Click for more articles on USFDA

Lupin had earlier received 13 observations from the USFDA after an inspection at its US-based wholly-owned subsidiary Novel Laboratories, Inc.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle East regions.

Click for more articles on Lupin

The company spacializes in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas.

Lupin is the third largest pharmaceutical company in the U.S. by prescriptions. The company invested 9.6% of its revenue on research and development in FY21.Lupin has 15 manufacturing sites, 7 research centres, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Other observations by USFDA

USFDA gives 13 observations to Lupin

USFDA complete audit of Granules Pharmaceuticals with 3 observations

USFDA issues 3 observations on Zydus manufacturing unit

USFDA issues 3 observations to Granules Pharmaceuticals Inc

USFDA completes audit at MSN Pharma with zero observations

USFDA issues 6 observations to Biocon’s Malaysian facility

Certain Products recalled due to Microbial Contamination

USFDA approves Cell Therapy for earlier lymphoma

Drug Recall: IDArubicin Hydrochloride Injection recalled due to this reason

USFDA gives 13 observations to Lupin

Govt further extends timeline to apply for slots under PLI scheme

CDSCO panel gives nod to Roche for Anticancer Drug Entrectinib Capsules

Nutraceuticals Regulations 2022 to encourage Pharma Industry

Telangana to fill posts of 18 Drug Inspectors, 442 Pharmacists and 15 junior Analysts

NPPA updated price lists: Download

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/?p=36570